OKYO Pharma (OKYO) vs Tenaya Therapeutics (TNYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
OKYO Pharma (OKYO) has outperformed Tenaya Therapeutics (TNYA) over the past year, losing 49.5% versus a loss of 76.7%. Tenaya Therapeutics is the larger company by market cap ($65.3 million vs $56.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OKYO | TNYA |
|---|---|---|
| Share price | $1.07 | $0.2866 |
| Market cap | $56.15M | $65.32M |
| 1-day change | -7.76% | -3.99% |
| YTD return | -48.31% | -59.75% |
| 1-year return | -49.53% | -76.70% |
| 5-year return | — | -98.50% |
| EPS (TTM) | $-0.24 | $-0.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-4.71M | $-90.60M |
| 52-week high | $3.20 | $1.46 |
| 52-week low | $1.00 | $0.28 |
| Distance from 52-week high | -66.56% | -80.37% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +678.50% | +1016.54% |
| Average volume | 143.41K | 2.96M |
| Shares outstanding | 52.48M | 227.93M |
| Employees | 5 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OKYO has outperformed TNYA by 27.2 percentage points over the past year.
About OKYO Pharma
OKYO stock →OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
About Tenaya Therapeutics
TNYA stock →Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees
OKYO vs TNYA FAQ
Which is bigger, OKYO Pharma or Tenaya Therapeutics?
Tenaya Therapeutics (TNYA) is larger, with a market capitalization of $65.32M compared with $56.15M for OKYO Pharma (OKYO).
Which stock has performed better over the past year, OKYO or TNYA?
OKYO returned -49.53% over the past 12 months, compared with -76.70% for TNYA (price return, excluding dividends). Past performance does not predict future results.
Are OKYO Pharma and Tenaya Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.